Synthesis and Antitubercular Evaluation of Some Novel 1,2,3,6-tetrahydropyrimidine-5-carbonitrile by Boukthir, Mouna et al.
    ISSN 2321-807X 
2072 | P a g e                                                            M a y  1 9 ,  2 0 1 4  
Synthesis and Antitubercular Evaluation of Some Novel 1,2,3,6-
tetrahydropyrimidine-5-carbonitrile 
Mouna Boukthir1, Fathi Zribi1*, Iman Halloum2, Laurent Kremer2,3 and Fakher Chabchoub1 
1
Laboratoire de Chimie Appliquée : Hétérocycles, Corps gras et Polymères à la Faculté des Sciences de Sfax. 
Route de Soukra Km 3.5. BP 802. Sfax 3000. Tunisia 
Email: monabokthir@yahoo.fr 
2
Laboratoire de Dynamique des Interactions Membranaires Normales et Pathologiques, CNRS UMR5235, 
Université Montpellier 2, Montpellier, France ; 
3
Inserm, DIMNP, Place Eugène Bataillon, 34095 Montpellier Cedex 05, France. 
*Corresponding author:  zfnfethi@yahoo.fr
ABSTRACT 
In an attempt to find a new class of antitubercular agents, a series of 1,2,3,6-tetrahydropyrimidine-5-carbonitrile were 
prepared via the reaction  of ethyl N-ethoxycarbonylbenzimidate 2a-b with cyanoacetanilide derivatives 1a-c. These 
compounds were screened for their antitubercular activity against M. tuberculosis. Several analogues, such as 2,6-dioxo-
1-phenyl-4-p-tolyl-1,2,3,6-tetrahydropyrimidine-5-carbonitrile 3a, 1-benzyl-2, 6-dioxo-4-p-tolyl-1,2,3,6-tetrahydropyrimidine-
5-carbonitrile 3c and 1-benzyl-2, 6-dioxo-4-phenyl-1,2,3,6-tetrahydropyrimidine-5-carbonitrile 3d exhibited a potent 
antitubercular activity with an MIC values ranging from 10-35 µg/ml. Structures of the newly synthesized compounds were 
established by spectral data and HRMS. 
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INTRODUCTION 
         Human tuberculosis (TB), mainly caused by Mycobacterium tuberculosis, is a major cause of illness and death 
worldwide
1
. In 2008, there were an estimated 8.9–9.9 million incident cases of TB, 9.6–13.3 million prevalent cases of TB, 
1.1–1.7 million deaths from TB among HIV-negative people, and an additional 0.45–0.62 million TB deaths among HIV-
positive people
2
.
 
During the recent years, pyrimidine derivatives have attracted organic chemists very much due to their 
antitubercular activity
3-7
. A series of 1,2,3,6-tetrahydropyrimidine-5-carbonitrile have demonstrated diverse 
pharmacological activities. The most pronounced of which are antitubercular
8
 anticancer
9.10
, antimicrobial
11 
and anti-
inflammatory 
12-15
. In connection with our previous work and continuing interest in the synthesis of valuable heterocycles 
16-18
, we report here the synthesis of some novel 1,2,3,6-tetrahydropyrimidine-5-carbonitrile  where we have examined the 
reaction of alkyl N-cyanobenzimidate, phenyl N-acetybenzimidate   with  cyanoacetanilide derivatives.  
RESULTS AND DISCUSSION 
         The solvent-free reaction of arylamines with ethyl cyanoacetate constitutes one of the most widely used methods for 
the preparation of cyanoacetanilides. Thus, fusion of aromatic amines with an excessive amount of ethyl cyanoacetate at 
150°C afforded cyanoacetanilide derivatives 1a-c 
19
, (Scheme 1). 
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Scheme 1: Synthesis of cyanoacetanilide derivatives 
 
         Our approach to the target heterocyclic compounds was achieved by the synthesis of 1,2,3,6-tetrahydropyrimidine-5-
carbonitrile derivatives 3a-f  which were prepared by stirring  equimolar amounts of cyanoacetanilide derivatives 1a-c with 
ethyl N-ethoxycarbonylbenzimidate 2a-b, under  basic medium. A reasonable mechanism for the formation of the products 
is outlined in scheme 2. Initially, the nonisolable intermediate 3’ a-f is formed by condensation of the cyanoacetanilide salt 
and ethyl N-ethoxycarbonylbenzimidate 2, then, followed by nucleophilic attack (by the NH group) on the ester group with 
the loss of an ethanol molecule to give 3a-f (Scheme 2).  
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Scheme 2: Synthetic route to 1,2,3,6-tetrahydropyrimidine-5-carbonitrile 3a-f 
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Table 1: Chemical structure of target compounds 
 Compound R1 R2 Yields 
(%) 
3a p-CH3 C6H4 C6H5 78 
3b C6H5 C6H5 65 
3c p-CH3 C6H4 C6H5-CH2 62 
3d C6H5 C6H5-CH2 66 
3e p-CH3 C6H4 o-CH3 C6H4 57 
3f C6H5 o-CH3 C6H4 50 
  
         The structures of compounds 3a-f are in accordance with their spectroscopic data. These new products were 
assigned by IR, NMR and mass spectroscopy. The IR spectra showed essentially the characteristic absorption bands of 
cyano group at around 2225 cm
-1
. In the 
1
HNMR spectra we have noticed the disappearance of the triplet and the 
quadruplet of ethoxy groups of the starting reagent. HRMS gave the molecular ion peak for all compounds. 
         Under the same experimental conditions, we have studied the condensation of compound 1a-c with ethyl N-
acetylbenzimidate 4. The formed products are acetamido-2-cyano-phenylacrylamide 5a-c. The reaction is drawn in 
schema 3. The intracyclisation observed in scheme 2 is not present here.  
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Scheme 3: Synthetic route to acetamido-2-cyano-phenylacrylamide 5a-c 
         IR spectra showed the characteristic absorption bands corresponding to NH and CN functionalities respectively at 
around 3312 and 2212 cm
-1
. Besides, two bands at 1714 and 1670 cm
-1
 attributed to C=O groups (5a-c). Additionally 
1
H 
NMR spectra indicated a singlet at around 2.4ppm due to CH3 protons (5a-c) and the most significant information was the 
disappearance of the triplet and quadruplet of ethoxy groups present in the starting reagent 4.  
Susceptibility of M. tuberculosisto 1,2,3,6-tetrahydropyrimidine-5-carbonitrile analogues 
We have evaluated the potential of 1,2,3,6-tetrahydropyrimidine-5-carbonitrile compounds in inhibiting growth of M. 
tuberculosis. Minimal inhibitory concentrations (MICs) were determined and are provided scheme 4. Several analogues, 
such as 3a, 3c and 3d exhibited a potent antitubercular activity with an MIC values ranging from 10-35 µg/ml, whereas 3b, 
3f and 5c exhibited only a modest activity. Compound 5a failed to show any growth inhibition activity even at 100µg/ml, 
the highest concentration tested.SAR studies seem to indicate that the presence of methyl group on first ring improves the 
activity of the molecules (compare 3a and 3b). Additionally, the presence of the methylene group next to the second 
aromatic ring appears to slightly improve the activity (compare 3c and 3a). 
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Table 2: Structures of the novel 1,2,3,6-tetrahydropyrimidine-5-carbonitrile and their corresponding minimum inhibitory 
concentrations in M. tuberculosis 
Compound Structure MIC (ug/ml) 
3a 
H3C N
NH
O
NC O  
25 
3b 
N
NH
O
NC O  
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H3C N
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O
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O
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CONCLUSION 
         In conclusion, we have developed a simple, quick and efficient method for the synthesis of new 1,2,3,6-
tetrahydropyrimidine-5-carbonitrile and acetamido-2-cyano-N,3 diphenylacrylamide using catalytic amounts of sodium 
ethoxide. Our results demonstrate that ethyl N-ethoxycarbonylbenzimidate and ethyl N-acetylbenzimidate react differently 
with the 3.  Different skeletons of heterocyclic compounds, obtained in reasonably good yields. The potent antitubercular 
activity recorded for some of these compounds may provide further insight into a novel mechanism by which these 
heterocycling compounds are involved in diverse pharmacological processes. 3c, the most active compound may 
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represent a scaffold for subsequent structure-activity relationship studies for subsequent pharmacological improvements 
against M. tuberculosis. 
EXPERIMENTAL 
Melting points are recorded in degrees Celsius on a Kofler apparatus. All reactions were followed by TLC (E. Merck 
Kieselgel 60 F-254), with UV detection at 254 nm.  The IR spectra were recorded in the solid state as KBr discs on a 
Perkin-Elmer PARAGON 1000 FT-IR spectrometer. 
1
H and 
13
C NMR were determined in solution in DMSO-d6 with an AC 
Bruker spectrometer at 300 MHz using TMS as an internal standard. High resolution mass were recorded on a 
spectrometer JEOL JMS-Gemate II. 
PROCEDURE FOR THE SYNTHESIS OF COMPOUNDS 3a-f AND 5a-c 
      To a magnetically stirred solution of sodium (10
-2
mol) in dry ethanol (30 mL) and cyanoacetanilide derivatives 1a-c 
(10
-2
mol), the appropriate imidate (10
-2
mol) were added and the reaction mixture stirred for 12 h at room temperature. The 
progress of the reaction was monitored by TLC (mobile phase, diethyl ether: hexane; 80/20;v/v). The solvent was removed 
in vacuo. The contents of the flask were neutralized by a saturated solution of NH4Cl, and then extracted by diethyl ether. 
The organic layer was dried over anhydrous Na2SO4. The solvent was removed in vacuo. The precipitate formed was 
isolated by filtration and washed with diethyl ether to obtain the pure product. 
Spectral Data of New Compounds 
2,6-dioxo-1-phenyl-4-p-tolyl-1,2,3,6-tetrahydropyrimidine-5-carbonitrile (3a): Yield (78%), mp >264°C, IR (KBr) ν: 
3414 (NH); 2222 (CN); 1742 (C=O); 1648 (C=O) cm
-1
,
 1
H NMR (DMSO-d6 ) : δ=2.50 (s,3H,CH3); 7.31-7.72 (m,9H,Harom); 
12.39(s,1H,NH), 
13
C-NMR (DMSO-d6) δ = 21.0 ( CH3); 86.2 (C5); 115.0 (CN); 149.8 (C6); 160.6 (C2); 160.9 (C4); 126.8-
142.6(Carom), HRMS: (M+) calcd 303.1008    found 303.0998. 
2,6-dioxo-1,4-diphenyl-1,2,3,6-tetrahydropyrimidine-5-carbonitrile (3b): Yield (65%), mp >264°C, IR (KBr) ν: 3204 
(NH); 2239 (CN); 1731 (C=O); 1692 (C=O) cm
-1
, 
1
H NMR (DMSO-d6 ) : δ=7.45-7.91 (m,10H,Harom); 8.63 (s,1H,NH),
 13
C-
NMR (DMSO-d6): δ = 86.4 (C5); 114.7 (CN); 149.7 (C6); 161.0 (C2); 162.2 (C4); 128.1-134.6(Carom), HRMS:(M+) calcd 
289.0851 found 289.0847.                                                                                                                                                       
1-benzyl-2, 6-dioxo-4-p-tolyl-1,2,3,6-tetrahydropyrimidine-5-carbonitrile (3c): Yield (62%), mp: >264°C, IR (KBr) ν:  
3201 (NH); 2228 (CN); 1722 (C=O); 1712 (C=O) cm
-1
, 
1
HNMR (DMSO-d6): δ=2.48 (s,3H,CH3); 5.13(s,2H,CH2); 7.23-
7.77(m,9H,Harom); 10.75(s,1H,NH), 
13
C-NMR (DMSO-d6): δ = 21.7 ( CH3), 44.5 ( CH2), 87.5 (C5), 114.0 (CN), 151.2 (C6), 
158.7 (C2), 160.1 (C4), 126.0-144.5(Carom); HRMS: (M+) calcd 317.1164   found 317.1161.                                                                                                                                                           
1-benzyl-2, 6-dioxo-4-phenyl-1,2,3,6-tetrahydropyrimidine-5-carbonitrile (3d): Yield (66%), mp: >260°C, IR (KBr) ν:  
3204 (NH); 2239 (CN); 1731 (C=O);  1692 (C=O) cm
-1
, 
1
H NMR (DMSO-d6) : δ=5.01 (s,2H,CH2); 7.24-7.77(m,10H,Harom); 
8.32(s,1H,NH), 
13
C-NMR (DMSO-d6): δ = 43.2 ( CH2), 84.0 (C5); 116.3 (CN); 151.9 (C6); 161.6 (C2); 163.2 (C4); 126.9-
136.9(Carom), HRMS: (M+) calcd 303.1008  found 303.1005.                                                                                                  
2, 6-dioxo-1-o-tolyl-4-p-tolyl-1,2,3,6-tetrahydropyrimidine-5-carbonitrile (3e):Yield (57%), mp: >260°C, IR (KBr) ν: 
3223 (NH); 2227(CN); 1721 (C=O);  1656 (C=O) cm
-1
, 
1
HNMR(DMSOd6):δ=1.98(s,3H, CH3); 2.05(s,3H, CH3); 6.81-
7.61(m,8H,Harom); 12.04(s,1H,NH), 
13
C-NMR(DMSO-d6): δ = 19.4 ( CH3); 19.5 ( CH3); 85.6 (C5); 114.4 (CN); 149.3 (C6); 
161.3 (C2); 161.7 (C4); 126.3-142.3(Carom), HRMS: (M+) calcd 317.1164  found 317.1143.                                                 
2, 6-dioxo-4-phenyl-o-tolyl-1,2,3,6-tetrahydropyrimidine-5-carbonitrile (3f): Yield (50%), mp>260°C, IR (KBr) ν: 3223 
(NH); 2227 (CN); 1721 (C=O);   1656 (C=O) cm
-1
, 
1
HNMR(DMSOd6): δ=2.14(s,3H,CH3); 7.27-7.81(m,9H,Harom); 
12.60(s,1H,NH), 
13
C-NMR(DMSO-d6): δ = 16.9 ( CH3); 86.4 (C5); 115.0 (CN);149.3 (C6); 160.2 (C2); 161.3 (C4); 126.7-
135.7(Carom), HRMS: (M+) calcd 303.1008  found 303.1004.                                                                                                 
3-acetamido-2-cyano-N,3-diphenylacrylamide (5a): Yield (25%), mp=252°C, IR (KBr) ν: 3296 (NH); 2209 (CN); 1701 
(C=O);    1636 (C=O) cm
-1
, 
1
HNMR(DMSOd6): δ=2.46 (s,3H, CH3); 7.06-8.04(m,12H,Harom + 2NH ). 
13
CNMR(DMSO-d6): 
24.4(CH3); 95.6 (C2); 115.4 (CN), 160.1(C1), 164.3(C3), 167.0 (CO); 124.9-136.3(Carom),  HRMS: (M+) calcd 305.1164 
found 305.1168.                                                                                                                                                                      
3-acetamido-N-benzyl-2-cyano-3-phenylacrylamide (5b): Yield (32%), mp >260°C, IR (KBr) ν: 3312 (NH); 2212 (CN); 
1696 (C=O); 1661 (C=O)  cm
-1
,
 1
HNMR(DMSOd6): δ=2.49 (s,3H, CH3), 5.37 (s, 2H, CH2), 7.27-8.04 (m,12H,Harom + 2NH ), 
13
CNMR(DMSO-d6): 23.5 (CH3), 47.3 (CH2); 85.4 (C2); 115.5 (CN); 160.4 (C1); 164.5 (C3); 166.7 (CO); 126.7-
138.7(Carom), HRMS: (M+) calcd 319.1321  found 319.1319.                                                                                                 
3-acetamido-2-cyano-3-phenyl-N-o-tolylacrylamide (5c): Yield (22%), mp >260°C, IR (KBr) ν: 3174 (NH); 2231 (CN); 
1734 (C=O); 1672 (C=O)  cm
-1
, 
1
HNMR(DMSOd6):δ=2.22(s,3H, CH3); 2.39(s,3H, CH3); 7.07-8.00 (m,11H,Harom+ 2NH), 
13
CNMR(DMSO-d6):20.7(CH3); 24.5(CH3); 95.5 (C2); 115.6 (CN); 160.3(C1); 163.3 (C3); 167.0 (CO);  127. 2-139.2(Carom).                                                     
Mycobacterial strain and growth conditions 
M. tuberculosis mc
2
6230 strain was grown at 37°C in Sauton’s medium supplemented with 24 µg/ml of pantothenic acid.  
Drug susceptibility testing or MIC determination 
The susceptibility to the various compounds was assessed visually by growth inhibition on Middlebrook 7H10 plates 
supplemented with oleic-albumin-dextrose-catalase enrichment (OADC), pantothenic acid and increasing concentrations 
of each test compound including a control plate without antimicrobial agent. Chemicals stocks were prepared in DMSO for 
dilution. Tenfold serial dilutions of each actively growing culture were plated and incubated at 37°C for 10 to 14 days. The 
minimal inhibitory concentration (MIC) was determined as the minimum concentration required to inhibit 99% of the 
bacterial growth.  
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